Patents by Inventor Brian Hoel
Brian Hoel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230190930Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.Type: ApplicationFiled: June 13, 2022Publication date: June 22, 2023Applicant: MUSC Foundation for Research DevelopmentInventors: Daniel FERNANDES, Laura Schwartz, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
-
Patent number: 11357849Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.Type: GrantFiled: March 7, 2017Date of Patent: June 14, 2022Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Daniel Fernandes, Laura Schwartz, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
-
Publication number: 20190382478Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.Type: ApplicationFiled: June 27, 2019Publication date: December 19, 2019Inventors: Natalie Sutkowski, Daniel Fernandes, Brian Hoel, Semyon Rubinchik
-
Patent number: 10385128Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.Type: GrantFiled: December 17, 2015Date of Patent: August 20, 2019Assignee: MUSC Foundation for Research DevelopmentInventors: Natalie Sutkowski, Daniel Fernandes, Brian Hoel, Semyon Rubinchik
-
Publication number: 20190194334Abstract: The present disclosure provides anti-nucleolin antibodies, methods of producing anti-nucleolin antibodies, and cells producing anti-nucleolin antibodies. Also provided are methods of using anti-nucleolin antibodies in treating malignant and non-malignant diseases.Type: ApplicationFiled: March 7, 2017Publication date: June 27, 2019Inventors: Daniel Fernandes, Laura Schwarts, Natalie Sutkowski, Brian Hoel, Semyon Rubinchik
-
Publication number: 20160215050Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.Type: ApplicationFiled: December 17, 2015Publication date: July 28, 2016Inventors: Natalie SUTKOWSKI, Daniel FERNANDES, Brian HOEL, Semyon RUBINCHIK
-
Patent number: 9260517Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.Type: GrantFiled: November 17, 2010Date of Patent: February 16, 2016Assignee: MUSC Foundation for Research DevelopmentInventors: Natalie Sutkowski, Daniel Fernandes, Brian Hoel, Semyon Rubinchik
-
Publication number: 20130115674Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysi-ology of the disease.Type: ApplicationFiled: November 17, 2010Publication date: May 9, 2013Applicant: Musc Foundation for Research DevelopmentInventors: Natalie Sutkowski, Daniel Fernandes, Brian Hoel, Semyon Rubinchik
-
Patent number: 7732197Abstract: The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5? and/or 3? autocatalytically cleaving ribozymes.Type: GrantFiled: February 26, 2002Date of Patent: June 8, 2010Assignees: The Penn State Research Foundation, MUSC Foundation for Research DevelopmentInventors: James S. Norris, Gary A. Clawson, Michael G. Schmidt, Brian Hoel, Wei-Hua Pan, Joseph W. Dolan
-
Patent number: 7575918Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: GrantFiled: September 8, 2004Date of Patent: August 18, 2009Assignee: The Penn State Research FoundationInventors: James Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael G. Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan
-
Publication number: 20060223774Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: ApplicationFiled: March 13, 2006Publication date: October 5, 2006Inventors: James Norris, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Gary Clawson, Wei-Hua Pan
-
Publication number: 20050118719Abstract: The invention provides methods and materials involved in delivering nucleic acid to cells and regulating expression of nucleic acid in cells.Type: ApplicationFiled: November 7, 2002Publication date: June 2, 2005Inventors: Michael Schmidt, David Schofield, Caroline Westwater, Joseph Dolan, Brian Hoel, Philip Werner, James Norris, Laura Kasman
-
Publication number: 20050107326Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: ApplicationFiled: September 8, 2004Publication date: May 19, 2005Inventors: James Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan
-
Publication number: 20030092651Abstract: The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5′ and/or 3′ autocatalytically cleaving ribozymes.Type: ApplicationFiled: February 26, 2002Publication date: May 15, 2003Applicant: Medical University of South Carolina, an agency of the State of South CarolinaInventors: James S. Norris, Gary A. Clawson, Michael G. Schmidt, Brian Hoel, Wei-Hua Pan, Joseph W. Dolan, David Schofield, Caroline Westwater, Cancan Huang
-
Patent number: 6271359Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.Type: GrantFiled: April 14, 1999Date of Patent: August 7, 2001Assignees: MUSC Foundation for Research Development, The Penn State Research FoundationInventors: James Norris, Gary Clawson, Caroline Westwater, David Schofield, Michael Schmidt, Brian Hoel, Joseph Dolan, Wei-Hua Pan